OMTN, Volume 16

Supplemental Information

Targeted Transgene Activation

in the Brain Tissue by Systemic Delivery

of Engineered AAV1 Expressing CRISPRa

Cia-Hin Lau, Jonathan Weng-Thim Ho, Pik Kwan Lo, and Chung Tin

SUPPLEMENTAL FIGURES



Figure S1. Flow Cytometry Analysis to Quantify iRFP720 and GFP Expressing Cells. (A) Flow cytometry analysis of mouse N2a cells after transfected with iRFP720-GFP fusion vector driven by different promoters. (B) Flow cytometry analysis of mouse N2a cells after transfected with iRFP or GFP alone. Two days after plasmids transfection, the iRFP720- and GFP-expressing cells were analysed with flow cytometry. The fluorescent channels APC-H7 and FITC were used to detect the iRFP720- and GFP-expressing cells, respectively.



⁺ dSaCas9-VP64 C36

N2a + pSyn1-iRFP720-GFP + dSaCas9-VP64 C34-C35-C36

Figure S2. CRISPR-mediated Modulation of Bicistronic Infrared-GFP Fluorescent Reporter Genes Expression in Mouse N2a Cells. (A) sgRNA target sites on hSyn1 promoter and iRFP720. The location of three different sgRNA target sites of dSaCas9-VP64 designed to target the hSyn1 promoter, and three different sgRNA target sites of SaCas9 designed to target the iRFP720 open reading frame are shown. Red arrows indicate the sense or antisense orientation of sgRNAs designed to recognize target DNA sequences. (B) Cellular images of GFP protein expression in mouse N2a cells. Two days after plasmids cotransfection of various CRISPR and iRFP720-GFP reporter genes, cellular images of GFP protein expression were taken under fluorescent microscope at 4X magnification. The left and right panels are phase contrast and GFP fluorescent images, respectively.



Figure S3. Ex Vivo Imaging of the Dissected Dorsal Brain Tissues. Ex vivo imaging was carried out to detect and quantify the (A) GFP and (B) iRFP720 fluorescent signals on the mouse dorsal brains. AAV1-PHP.B expressing dSaCas9-VP64 was injected together with AAV1-PHP.B expressing iRFP720 and GFP fluorescent proteins. The statistical significance levels are indicate as P<0.05, *P<0.01 and **P<0.001. All data are presented as mean \pm standard deviation.



Figure S4. Immune Responses Inhibit CRISPRa-mediated Transgene Activation in the Mouse Brains. AAV1-PHP.B expressing dSaCas9-VP64 was introduced into the mice only after 24 hours tail-vein injection of AAV1-PHP.B expressing iRFP720 and GFP fluorescent proteins. Ex vivo imaging was carried out to detect and quantify the GFP (left) and iRFP720 (right) fluorescent signals on the mouse (A) dorsal and (B) ventral brains. The statistical significance levels are indicate as *P<0.05, **P<0.01 and ***P<0.001. All data are presented as mean \pm standard deviation.

SUPPLEMENTAL TABLES

Table S1. Primers used for SaCas9s and dSaCas9-based CRISPR Backbone Construction

Amplicon	Description
Size (bp)	
-	68 bp DNA fragment bearing EcoRI-spA-KpnI for CRISPR
	backbone construction
268	PCR pMecp2 with added Xbal
	PCR pMecp2 with added Agel
177	PCR VP64 with added BamHI
	PCR VP64 with added EcoRI-Stop
414	PCR VP160 with added BamHI
	PCR VP160 with added EcoRI-Stop
237	PCR KRAB with added BamHI
	PCR KRAB with added EcoRI-Stop
429	PCR SID4X with added BamHI
	PCR SID4X with added EcoRI-Stop
-	Sequencing BamHI-domain-spA
-	Sequencing dSaCas9 (mutation N580A)
-	Sequencing pMecp2-dSaCas9 (mutation D10A)
	Amplicon Size (bp) 268 177 414 237 429

Table S2. Primers used for Single Guide RNAs Designed

Primer Sequence (5' to 3')	Target	Description
(Forward, FP; Reverse, RP)	sequence	
	(bp)	
FP: CACC GGGCGAGCAGCAGTCCATGCGG	22	SaCas9-37 construction for exonic knockout of iRFP720
RP: AAAC CCGCATGGACTGCTGCTCGCCC		
FP: CACC GGTTTCGGCGGCCTGCAGGCG	21	SaCas9-38 construction for exonic knockout of iRFP720
RP: AAAC CGCCTGCAGGCCGCCGAAACC		
FP: CACC GGCTCTATACCATCAACCCGGT	22	SaCas9-39 construction for exonic knockout of iREP720
	21	dSaCac0.34 construction for modulating promotor activity of hSup1
	21	usacass-s4 construction for modulating promoter activity of hoyn
	22	dCaCaa0.25 construction for modulating promotor activity of hCup1
	22	dSaCase-55 construction of modulating promoter activity of hSynt
	04	
	21	dSaCas9-36 construction for modulating promoter activity of hSyn1
RP: AAAC CITCCCGGCCACCTIGGTCGC	24	
FP: CACC GIGIGAAGGIGCIGGCIGGIC	21	SaCas9-40 construction for exonic knockout of mouse alpha CaMKII
RP: AAAC GACCAGCCAGCACCIICACAC		
FP: CACC GATACCCAACCAGCAAGATATA	22	SaCas9-41 construction for exonic knockout of mouse alpha CaMKII
RP: AAAC TATATCTTGCTGGTTGGGTATC		
FP: CACC GGACACCGTCACCCCAGAAGCC	22	SaCas9-42 construction for exonic knockout of mouse alpha CaMKII
RP: AAAC GGCTTCTGGGGTGACGGTGTCC		
FP: CACC GACTCGTCAGCTTGTGGATGAG	22	dSaCas9-9 construction for modulating distal super-enhancer activity of mouse
RP: AAAC CTCATCCACAAGCTGACGAGTC		alpha CaMKII
FP: CACC GCGTAGGTTGTGTGTATTTGTGT	21	dSaCas9-8 construction for modulating distal super-enhancer activity of mouse
RP: AAAC ACACAAATACACAACCTACGC		alpha CaMKII
FP: CACC GCCAGGGTGGCAAGCCAGCAAG	22	dSaCas9-7 construction for modulating distal super-enhancer activity of mouse
		alnha CaMKII
	22	dSaCasQ 6 construction for modulating provinal super enhancer activity of mouse
	22	
	22	dipita Calvinti
	22	usacases construction for modulating proximal super-eminancer activity of mouse
	00	
	22	dSaCas9-4 construction for modulating proximal super-enhancer activity of mouse
RP: AAAC GGACCTGCCTATCCCTTAGCCC		alpha CaMKII
FP: CACC GAGCAAGIGGACCCIGIICCCC	22	dSaCas9-1 construction for modulating promoter activity of mouse alpha CaMKII
RP: AAAC GGGGAACAGGGTCCACTTGCTC		
FP: CACC GCAGTTGCTATGGTAACGGCTA	22	dSaCas9-2 construction for modulating promoter activity of mouse alpha CaMKII
RP: AAAC TAGCCGTTACCATAGCAACTGC		
FP: CACC GAGAAGAAGTACCAAACAGACC	22	dSaCas9-3 construction for modulating promoter activity of mouse alpha CaMKII
RP: AAAC GGTCTGTTTGGTACTTCTTCTC		
FP: CACC GAGAAGCAGACCAGATGGGATG	22	dSaCas9-30 or dSaCas9-31 construction for modulating promoter activity of human
RP: AAAC CATCCCATCTGGTCTGCTTCTC		PDGFRA
FP: CACC GAGGGCCCTATTTCTCGTTGGG	22	dSaCas9-29 construction for modulating promoter activity of human PDGFRA
RP: AAAC CCCAACGAGAAATAGGGCCCTC		
FP: CACC GTTGAGTCCAATATGACAATG	21	dSaCas9-28 construction for modulating promoter activity of human PDGERA
RP AAAC CATTGTCATATTGGACTCAAC		
	22	dSaCas9-32 construction for modulating expression level of human PDGER4
	22	
	22	dSaCasQ 33 construction for modulating expression loval of human PDCEPA
	22	usacass-ss construction for modulating expression level of number PDGFRA
	04	do-o-o to sensitive for much letting any start it of much liter
	21	dSaCas9-10 construction for modulating promoter activity of mouse Mych
RP: AAAC GTGTCGCCTTCCTTCGAGATC		
FP: CACC GGAGTGCAGCGGGTGCAAGCCA	22	dSaCas9-11 construction for modulating promoter activity of mouse Mycn
RP: AAAC IGGCIIGCACCCGCIGCACICC		
FP: CACC GACAGTCATCTGTCTGGACGCG	22	dSaCas9-12 or dSaCas9-13 construction for modulating promoter activity of mouse
RP: AAAC CGCGTCCAGACAGATGACTGTC		Мусп
FP: CACC GGATCCGGAGGCGACTCGGGGC	22	dSaCas9-14 construction for modulating expression level of mouse Mycn
RP: AAAC GCCCCGAGTCGCCTCCGGATCC		
FP: CACC GTCTCTTCCAGCCAGGGTGCCT	22	dSaCas9-15 construction for modulating expression level of mouse Mycn
RP: AAAC AGGCACCCTGGCTGGAAGAGAC		
FP: CACC GCCCGAGGGCGGGGCATGGAC	21	dSaCas9-18 construction for modulating promoter activity of mouse Nrf2
RP: AAAC GTCCATGCCCCGCCCTCGGGC		
FP: CACC GCGAGAGGAGGATCAACAGTG	21	dSaCas9-17 construction for modulating promoter activity of mouse Nrf2
RP: AAAC CACTGTTGATCCTCCTCTCGC		······································

RP: AAAC ACTTTGCAAGAGGCCAACTGCC FP: CACC GGCAGGACAAGGGCATGGAGG 21 dSaCas9-19 construction for modulating expression level of mouse Nrf2 RP: AAAC CCTCCATGCCCTTGTCCTGCC EP: CACC GGAGGATGTTGGGGCCGCGAC 21 dSaCas9-20 construction for modulating expression level of mouse Nrf2
FP: CACC GGCAGGACAAGGGCATGGAGG 21 dSaCas9-19 construction for modulating expression level of mouse Nrf2 RP: AAAC CCTCCATGCCCTTGTCCTGCC 21 dSaCas9-20 construction for modulating expression level of mouse Nrf2 EP: CACC GGAGGATGTTGGGGCCGCGAC 21 dSaCas9-20 construction for modulating expression level of mouse Nrf2
RP: AAAC CCTCCATGCCCTTGTCCTGCC EP: CACC GGAGGATGTTGGGGCCGCGAC 21 dSaCas9-20 construction for modulating expression level of mouse Nrf2
EP: CACC GGAGGATGTTGGGGCCGCGAC 21 dSaCas9-20 construction for modulating expression level of mouse Nrf2
RP: AAAC GTCGCGGCCCCAACATCCTCC
FP: CACC GGCAGAGACACCACCACCTCG 21 dSaCas9-21 construction for modulating expression level of mouse Nrf2
RP: AAAC CGAGGTGGTGGTGTCTCTGCC
FP: CACC GTTGGACCGTGCAGGCTGTGG 21 dSaCas9-24 construction for modulating promoter activity of mouse Keap1
RP: AAAC CCACAGCCTGCACGGTCCAAC
FP: CACC GATAAATATCGCAACCAGGTAG 22 dSaCas9-23 construction for modulating promoter activity of mouse Keap1
RP: AAAC CTACCTGGTTGCGATATTTATC
FP: CACC GTGGAGCCTGCAAAGTGCAGC 21 dSaCas9-22 construction for modulating promoter activity of mouse Keap1
RP: AAAC GCTGCACTTTGCAGGCTCCAC
FP: CACC GCGGGAGGGCGGAAACGGGCG 21 dSaCas9-25 construction for modulating expression level of mouse Keap1
RP: AAAC CGCCCGTTTCCGCCCTCCCGC
FP: CACC GGCACCTACAGAGACACCCGG 21 dSaCas9-26 construction for modulating expression level of mouse Keap1
RP: AAAC CCGGGTGTCTCTGTAGGTGCC
FP: CACC GGTGGCCGCGGCGAGTAGAGGT 22 dSaCas9-27 construction for modulating expression level of mouse Keap1
RP: AAAC ACCTCTACTCGCCGCGGCCACC
FP: GCATATACGATACAAGGCTGTTAGAGAG - Sequencing pU6-sgRNA for successful of target sequence insertion

Table S3. Primers used for Luciferase Reporter Vectors Construction

Primer Sequence (5' to 3')	Amplicon	Description
(Forward, FP; Reverse, RP)	Size (bp)	
FP: AAAA GGTACC GAACCCCATTATGGCCTTAGGTCAC	1316	To insert amplified 1316bp mouse alpha CaMKII promoter into
RP: AAAA AAGCTT CTAGGGCTGGGATGCTGAAGC		pGL4.10[luc2] with KpnI and HindIII
FP: GTCCTGCCACAGGCTTACCATG	7kb	Nested PCR (outer primers) to amplify entire promoter and super-
RP: GTGATGGTAGCCATCCTGGCACT		enhancer regions of mouse alpha CaMKII
FP: AAAA GAGCTC GGGGTGGTTGTAGAGCCTGCTAG	6.8kb	Nested PCR (inner primers) to amplify entire promoter and super-
RP: AAAA AAGCTT CTAGGGCTGGGATGCTGAAGC		enhancer regions of mouse alpha CaMKII for inserting into pGL4.10[luc2] with SacI and HindIII
FP: TAGCAAAATAGGCTGTCCCCAGTG	-	Sequencing enhancer or promoter that has been cloned into
RP: CATGGTGGCTTTACCAACAGTACC		pGL4.10[luc2] firefly luciferase vector

Table S4. Primers used for PCR and Quantitative RT-PCR

Primer Sequence (5' to 3')	Amplicon	Description
(Forward, FP; Reverse, RP)	Size (bp)	
FP: ACCATCTTCCAGGAGCGAGA	319	gPCR mRNA expression level of human and mouse Gapdh
RP: TGGCATGGACTGTGGTCATG		
FP: GCTCAGCCCTGTGAGAAGAC	95	qPCR mRNA expression level of human PDGFRA
RP: ATTGCGGAATAACATCGGAG		
FP: TGATGCCAGCCACTGTATCC	194	qPCR mRNA expression level of mouse alpha CaMKII
RP: CTGCGAACCCAAACCATGC		
FP: CCTCCGGAGAGGATACCTTG	90	qPCR mRNA expression level of mouse Mycn
RP: TCTCTACGGTGACCACATCG		
FP: GATCCGCCAGCTACTCCCAGGTTG	122	qPCR mRNA expression level of mouse Nrf2
RP: CAGGGCAAGCGACTCATGGTCATC		
FP: CATTGGCATCGCCAACTTCG	188	qPCR mRNA expression level of mouse Keap1
RP: GGAACACCTCGGACTCGCA		

Table S5. Primers used for Construction of iRFP720-GFP Fusion Transgenes

Primer Sequence (5' to 3')	Amplicon	Description
(Forward, FP; Reverse, RP)	Size (bp)	
FP: AAAA ACCGGT ATGGCGGAAGGATCCGTCGC	948	To insert amplified 948bp iRFP720 into pAAV-pMecp2-SpCas9-spA by
RP: AAAA GAATTC CTCTTCCATCACGCCGATCTGC		replacing SpCas9 with AgeI and EcoRI
FP: AAAA GAATTC GAGGGCAGAGGATCCCTGCTA	774	To insert amplified 774bp T2A-GFP into pAAV-pMecp2-iRFP720-spA with
RP: AAAA GAATTC TTACTTGTACAGCTCGTCCATGCC		EcoRI
FP: AAAA TCTAGA GTGGATAACCGTATTACCGCCATGC	553	To insert amplified 553bp CMV promoter into pAAV-pMecp2-iRFP720-
RP: AAAA ACCGGT GCTAGCGGATCTGACGGTTCAC		T2A-GFP-spA by replacing pMecp2 with Xbal and Agel
FP: AAAA TCTAGA CGCGTGTGTCTAGACTGCAGAG	476	To insert amplified 476bp hSyn1 promoter into pAAV-pMecp2-iRFP720-
RP: AAAA ACCGGT GTACCTTCTCGACTGCGCTCTCA		T2A-GFP-spA by replacing pMecp2 with Xbal and Agel
FP: GCCATCACCGAACGCCGT	-	Sequencing T2A-GFP that has been cloned into pAAV-pSyn1-iRFP720-
		T2A-GFP-spA vector
FP: TTCATCGGCTCCTGGCATC	-	Sequencing iRFP720-T2A that has been cloned into pAAV-pSyn1-
		iRFP720-T2A-GFP-spA vector
RP: AGATCATCACCCGATCGAAGC	-	Sequencing pSyn1-iRFP720 that has been cloned into pAAV-pSyn1-
		iRFP720-T2A-GFP-spA vector
RP: ACCGCACAGATGCGTAAGGAG	-	Sequencing GFP-spA that has been cloned into pAAV-pSyn1-iRFP720-
		T2A-GFP-spA vector

Table S6. Primers used for Modification of AAV1 Capsid

Primer Sequence (5' to 3') (Forward, FP; Reverse, RP)	Amplicon Size (bp)	Description
FP: AAAATGGCCACCGAAAGATTTGGGACCGTGGCAGTCAATTTCCAGAGCAGCA GCACTTTGGCGGTGCCTTTTAAGACAGACCCTGCGACCGGAGATGTGCATGCA	-	108 bp DNA fragment bearing MscI-PHP.B-SphI for modification of AAV1 capsid
FP: TCCATCATCAACCCTGGCACTG	-	sequencing AAV1 capsid for validating 21bp of PHP.B sequence insertion

Table S7. Primers used for TaqMan qPCR

Primer Sequence (5' to 3') (Forward EP: Reverse BP)	Amplicon Size (bp)	Description
	0120 (00)	
6-FAM-AGCGCCATCCGCCGCCTGCA-ZEN/lowa	-	probe specific to iRFP720
FP: TTCATCGGCTCCTGGCATC	204	quantify the copies number of iRFP720 DNA
RP: AGATCATCACCCGATCGAAGC		
6-FAM-CACCACGCCGAGGACGCCCTGA-ZEN/lowa	-	probe specific to dSaCas9
FP: TCCATCAATGGCGGCTTCA	150	quantify the copies number of dSaCas9 DNA
RP: GGCCTTGTCCAGTTTCTTCCA		